RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States.
The last earnings update was 20 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
RedHill Biopharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
RedHill Biopharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
RedHill Biopharma's earnings are expected to grow significantly at over 20% yearly.
RedHill Biopharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
RedHill Biopharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
RedHill Biopharma's finances.
The net worth of a company is the difference between its assets and liabilities.
RedHill Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
RedHill Biopharma's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
RedHill Biopharma's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 16.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Dror Ben-Asher Co-Founded RedHill Biopharma Ltd. and has been its Chief Executive Officer since August 3, 2009. Mr. Ben-Asher serves as an Associate of Mercator Group, LLC. He has been affiliated with The Mercator Group since 1999. Mr. Ben-Asher has worked with Mercator on several projects including EquipNet, eCapitaledge.com, Tefron, Ltd. and Internet Media Group. He has extensive managerial and transactional expertise, He was with ProSeed Capital, a European corporate finance boutique. He was a Co-Founder of ProSeed Capital Holdings CVA and served as its President and Chief Executive Officer. He served as a Manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA from January 2002 to November 2010. He was a Co-Founder of ProSeed Venture I, L.P. and served as its President and Co-Chief Executive Officer. He served as a Consultant for a leading Israeli law firm and the Harvard International Law Journal at Harvard Law School. He served as an Officer in the Israeli Defense Forces. Mr. Ben-Asher has been the Chairman of RedHill Biopharma Ltd. since May 4, 2011 and has been its director since August 3, 2009. He serves as a Director of Agrea Ltd. He served as Director of ProSeed Venture I, L.P. He is writing his doctoral thesis at Harvard Law School. He concentrates on the pharmaceutical and medical devices industries and antitrust issues. He has a number of publications and teaches sections of graduates at Harvard Law School and undergraduates at Harvard's Economics department. At Harvard, he was a Fulbright Scholar focusing on the pharmaceutical industry and markets. He speaks fluent Hebrew and English and has some knowledge of Spanish. He is an Olin Fellow for Law, Economics and Business and an Economics Teaching Fellow at Harvard. He received his LL.B. with distinction (First Class Honours) from the University of Leicester. He is a graduate of the University of Oxford (M.Jur.). As an Oxford scholar, he received a Masters degree in European and Comparative Law from Oxford University, specializing in European business law, intellectual property and competition law. Mr. Ben-Asher completed LLM studies at Harvard University in the U.S.
Dror's compensation has been consistent with company performance over the past year, both up more than 20%.
Dror's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the RedHill Biopharma management team is about average.
Chief Financial Officer
Chief Operating Officer
Senior Vice President of Business Development & Licensing
Chief Business Officer
VP & Compliance Officer
Vice President of Business Development & Communications
Senior Vice President of Research & Development
COO of US Operation & Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the RedHill Biopharma board of directors is about average.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company’s clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors. It is also developing YELIVA that is in Phase IIa clinical trial for the treatment of advanced unresectable cholangiocarcinoma; is in Phase Ib/II clinical trial for refractory or relapsed multiple myeloma; and is in Phase II clinical trial for the treatment of advanced hepatocellular carcinoma. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.